scholarly journals Identifying Barriers to Entering Smoking Cessation Treatment Among Socioeconomically Disadvantaged Smokers

2010 ◽  
Vol 5 (2) ◽  
pp. 164-171 ◽  
Author(s):  
Amy L. Copeland ◽  
Michael S. Businelle ◽  
Diana W. Stewart ◽  
Scott M. Patterson ◽  
Carla J. Rash ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Nicotine Dependence ◽  
Stage Of Change ◽  
Psychosocial Treatment ◽  
Treatment Programs ◽  
Smoking Rate ◽  
Socioeconomically Disadvantaged ◽  
Smoking Cessation Treatment ◽  
Cessation Treatment ◽  
Professional Assistance

AbstractBackground:Efficacious smoking cessation interventions exist, yet few smokers utilise available resources such as psychosocial treatment programs and pharmacotherapy. The goals of the present study were to (1) identify perceived barriers to entering smoking cessation treatment programs among socioeconomically disadvantaged smokers, who are presently underrepresented in smoking cessation interventions; (2) determine what variables are most important in predicting the barriers identified (i.e., age, gender, ethnicity, income, nicotine dependence level, smoking rate, years smoking, stage of change, presence of smoking-related illness and medical insurance status).Methods:Responses from socioeconomically disadvantaged smokers (N= 343) were collected in 2004–2005 and analysed to develop the Treatment Barriers Questionnaire, a 40-item measure of reasons for not entering smoking cessation programs. Study methods were approved by the Institutional Review Board of Louisiana State University; informed consent procedures were employed.Results:Principal components analysis yielded seven scales named for their theme: (1) Preparedness to Quit Smoking; (2) Work and Time Constraints; (3) Smokers Can or Should Quit on Own; (4) Opinions about Professional Assistance; (5) Mobility Limitations; (6) Insurance Limitations and (7) Misinformation about Professional Assistance. Gender, ethnicity, daily smoking rate, nicotine dependence and stage of change were significant predictors in regression analyses for scales 1,F(10, 201) = 7.83,p< .001,R2= .29, 2F(10, 201) = 2.30,p< .05,R2= .11, and 3,F(10, 201) = 3.58,p< .001,R2= .16. Conclusions: Results can inform efforts to facilitate entry and retention of smokers in cessation programs.

scholarly journals Smoking Cessation Treatment among Rural Individuals

2020 ◽  
pp. 1-2
Author(s):  
Steven S. Coughlin ◽  
Steven S. Coughlin
Keyword(s):  
Smoking Cessation ◽  
Rural Areas ◽  
Evidence Based ◽  
Socioeconomically Disadvantaged ◽  
Smoking Cessation Treatment ◽  
Randomized Controlled Studies ◽  
Cessation Treatment ◽  
Poor Access ◽  
Access To Primary Care ◽  
Out Of Pocket Expenses

Rural population in the U.S. have higher smoking prevalence rates and consume a higher number of cigarettes per day. Socioeconomically disadvantaged smokers, such as those who reside in rural areas, are less likely to use and have access to evidence-based tobacco cessation treatments than the general population of smokers. Randomized controlled studies are needed to examine the effectiveness of evidence-based smoking cessation interventions among rural residents. Of particular interest are interventions that overcome barriers to smoking cessation treatment such as poor access to primary care, travel, time, lack of health insurance, an inability to pay out-of-pocket expenses for pharmacotherapy, and communal norms that influence smoking cessation.

scholarly journals A Novel Smoking Cessation Smartphone App Integrated With a Mobile Carbon Monoxide Checker for Smoking Cessation Treatment: Protocol for a Randomized Controlled Trial (Preprint)

2018 ◽  
Author(s):  
Akihiro Nomura ◽  
Hiroki Tateno ◽  
Katsunori Masaki ◽  
Tomoyasu Muto ◽  
Shin Suzuki ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Smoking Cessation ◽  
Nicotine Dependence ◽  
Controlled Trial ◽  
Smartphone App ◽  
Smoking Cessation Treatment ◽  
Randomized Controlled ◽  
Cessation Treatment ◽  
Co Concentration ◽  
Continuous Abstinence

BACKGROUND Smoking cessation treatment programs have been widely available for patients with nicotine dependence. Despite intensive programs, the continuous abstinence rate (CAR) from weeks 9-12 is still about 50%. Recently, a smartphone app emerged as a novel tool for therapeutic interventions, including nicotine dependence. In this study, we developed “CureApp Smoking Cessation” (CASC), which consists of a smartphone app for patients and a Web-based patient management software for doctors with a mobile carbon monoxide (CO) checking device to improve the efficacy of the smoking cessation treatment. OBJECTIVE This study aims to evaluate whether the CASC app is effective for individuals with nicotine dependence in addition to standard smoking cessation programs. METHODS This will be a randomized, sham-controlled, open-label, multicenter trial. We will recruit participants with nicotine dependence, but are otherwise healthy adults. We will randomize and allocate participants 1:1 to the CASC treatment group or a control app group. Both groups will receive a 12-week standard smoking cessation program with pharmacotherapy and counseling. In addition, participants in the treatment group will have the CASC app installed on their smartphone, which will provide video tutorials, advice from an artificial intelligence nurse, a digital diary, and measure daily exhaled CO concentration. In contrast, the control group will have the control app installed on their smartphone, where all the functions that can potentially effect smoking cessation are removed. The primary outcome will be the biochemically validated CAR from weeks 9-24. The success of smoking cessation will be defined as self-reported continuous abstinence from weeks 9-24 and exhaled CO concentration ≤10 ppm both at weeks 12 and 24. The main secondary outcomes will be the CAR from weeks 9-12, weeks 9-52, and 7-day point prevalence abstinence at weeks 4, 8, 12, 24, and 52. RESULTS We will recruit 580 participants with nicotine dependence from October 2017 to September 2018 or until the recruitment process is complete. The final 52-week follow-up will be completed in October 2019. We expect all trial results to be available by the end of 2019. The trial is funded by CureApp, Inc. CONCLUSIONS This is the first randomized controlled trial to evaluate the efficacy of CASC. We expect that CASC, in addition to standard smoking cessation programs, has a significantly higher CAR during weeks 9-24 than the control app. CLINICALTRIAL University Hospital Medical Information Network Clinical Trials Registry UMIN000031589; https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000033555 INTERNATIONAL REGISTERED REPOR DERR1-10.2196/12252

scholarly journals Financial Incentives for Abstinence Among Socioeconomically Disadvantaged Individuals in Smoking Cessation Treatment

2015 ◽  
Vol 105 (6) ◽  
pp. 1198-1205 ◽  
Author(s):  
Darla E. Kendzor ◽  
Michael S. Businelle ◽  
Insiya B. Poonawalla ◽  
Erica L. Cuate ◽  
Anshula Kesh ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Financial Incentives ◽  
Socioeconomically Disadvantaged ◽  
Smoking Cessation Treatment ◽  
Cessation Treatment

scholarly journals Smoking Cessation Treatment Programs Offered at Hospitals Providing Oncology Services

2018 ◽  
Vol 14 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Michael Shayne Gallaway ◽  
Eric Tai ◽  
Elizabeth A. Rohan
Keyword(s):  
Smoking Cessation ◽  
Tobacco Cessation ◽  
Treatment Programs ◽  
Treatment Cessation ◽  
Smoking Cessation Treatment ◽  
Treatment Services ◽  
Tobacco Treatment ◽  
Cessation Treatment ◽  
Quit Attempts ◽  
Discharged Patients

Background: Many people with cancer continue smoking despite evidence that it negatively effects cancer treatment, worsens chemotherapy toxicity, and increases risk for a second cancer.Aims: We examined tobacco treatment services offered to cancer patients at hospitals providing oncology services, including National Cancer Institute (NCI)-Designated Cancer Centers (NDCCs).Methods: We examined survey data of 6,400 U.S. hospitals from 2008 to 2015 to determine the manner in which tobacco treatment/cessation program services were provided among NDCCs and non-NDCC hospitals providing oncology services (HPOs).Results: From 2008 to 2015, 784 responses from NDCCs and 18,281 responses from HPOs were received. NDCCs (86%) reported significantly higher tobacco treatment/cessation programs owned by the hospital compared to HPOs (68%) (p < 0.001). Among NDCCs, there was a significant increasing trend of tobacco treatment/cessation programs reported owned by the hospital, the health system, or other contractual mechanism from 2008 to 2015 (p = 0.03).Conclusions: More than 80% of oncology providing hospitals report providing tobacco cessation programs, with higher percentages reported in NDCCs. As hospitals implement smoking cessation programs, partnerships between hospitals and cancer coalitions could help bring tobacco cessation activities to communities they both serve, and link discharged patients to these cessation resources so they can continue quit attempts that they initialised while hospitalised.

scholarly journals Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome

2014 ◽  
Vol 138 ◽  
pp. 109-117 ◽  
Author(s):  
Adam. M. Leventhal ◽  
Wonho Lee ◽  
Andrew W. Bergen ◽  
Gary E. Swan ◽  
Rachel F. Tyndale ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Treatment Outcome ◽  
Nicotine Dependence ◽  
Genetic Influences ◽  
Smoking Cessation Treatment ◽  
Cessation Treatment
Sign in / Sign up

Export Citation Format

Share Document